Tag Archive for: proarrhythmia

Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation

/in

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers Phase 2 trial will assess the efficacy of AP31969 on atrial fibrillation burden and its safety profile using continuous cardiac rhythm monitoring Copenhagen, Denmark, 6 January 2026 – Acesion […]

Read more

Acesion Pharma Announces Positive Pre-Clinical Data for AP31969

/in

Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces positive data from pre-clinical studies with AP31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent AF recurrence. Acesion aims to develop a […]

Read more